Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate alpha-synuclein fibrilization.

Bosco DA, Fowler DM, Zhang Q, Nieva J, Powers ET, Wentworth P Jr, Lerner RA, Kelly JW.

Nat Chem Biol. 2006 May;2(5):249-53. Epub 2006 Mar 26. Erratum in: Nat Chem Biol. 2006 Jun;2(6):346.

PMID:
16565714
2.

Patterns of protein nitration in dementia with Lewy bodies and striatonigral degeneration.

Gómez-Tortosa E, Gonzalo I, Newell K, García Yébenes J, Vonsattel P, Hyman BT.

Acta Neuropathol. 2002 May;103(5):495-500. Epub 2002 Feb 23.

PMID:
11935266
3.

Transgenic mice overexpressing tyrosine-to-cysteine mutant human alpha-synuclein: a progressive neurodegenerative model of diffuse Lewy body disease.

Zhou W, Milder JB, Freed CR.

J Biol Chem. 2008 Apr 11;283(15):9863-70. doi: 10.1074/jbc.M710232200. Epub 2008 Jan 30.

4.

Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions.

Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, Ischiropoulos H, Trojanowski JQ, Lee VM.

Science. 2000 Nov 3;290(5493):985-9.

5.

Role of cytochrome c as a stimulator of alpha-synuclein aggregation in Lewy body disease.

Hashimoto M, Takeda A, Hsu LJ, Takenouchi T, Masliah E.

J Biol Chem. 1999 Oct 8;274(41):28849-52.

6.
7.

Nuclear and neuritic distribution of serine-129 phosphorylated alpha-synuclein in transgenic mice.

Schell H, Hasegawa T, Neumann M, Kahle PJ.

Neuroscience. 2009 Jun 2;160(4):796-804. doi: 10.1016/j.neuroscience.2009.03.002. Epub 2009 Mar 9.

PMID:
19272424
8.

Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease.

Anderson JP, Walker DE, Goldstein JM, de Laat R, Banducci K, Caccavello RJ, Barbour R, Huang J, Kling K, Lee M, Diep L, Keim PS, Shen X, Chataway T, Schlossmacher MG, Seubert P, Schenk D, Sinha S, Gai WP, Chilcote TJ.

J Biol Chem. 2006 Oct 6;281(40):29739-52. Epub 2006 Jul 17.

9.

Clinical and biochemical correlates of insoluble alpha-synuclein in dementia with Lewy bodies.

Klucken J, Ingelsson M, Shin Y, Irizarry MC, Hedley-Whyte ET, Frosch M, Growdon J, McLean P, Hyman BT.

Acta Neuropathol. 2006 Feb;111(2):101-8. Epub 2006 Feb 16.

PMID:
16482476
10.

Small molecule oxidation products trigger disease-associated protein misfolding.

Bieschke J, Zhang Q, Bosco DA, Lerner RA, Powers ET, Wentworth P Jr, Kelly JW.

Acc Chem Res. 2006 Sep;39(9):611-9. Review.

PMID:
16981677
11.

In vitro characterisation of BF227 binding to alpha-synuclein/Lewy bodies.

Fodero-Tavoletti MT, Mulligan RS, Okamura N, Furumoto S, Rowe CC, Kudo Y, Masters CL, Cappai R, Yanai K, Villemagne VL.

Eur J Pharmacol. 2009 Sep 1;617(1-3):54-8. doi: 10.1016/j.ejphar.2009.06.042. Epub 2009 Jul 1.

PMID:
19576880
12.

Gelsolin co-occurs with Lewy bodies in vivo and accelerates α-synuclein aggregation in vitro.

Welander H, Bontha SV, Näsström T, Karlsson M, Nikolajeff F, Danzer K, Kostka M, Kalimo H, Lannfelt L, Ingelsson M, Bergström J.

Biochem Biophys Res Commun. 2011 Aug 19;412(1):32-8. doi: 10.1016/j.bbrc.2011.07.027. Epub 2011 Jul 21.

PMID:
21798243
13.
14.

Early alpha-synuclein lipoxidation in neocortex in Lewy body diseases.

Dalfó E, Ferrer I.

Neurobiol Aging. 2008 Mar;29(3):408-17. Epub 2006 Dec 12.

PMID:
17166629
15.

Low alpha-synuclein 126 mRNA levels in dementia with Lewy bodies and Alzheimer disease.

Beyer K, Humbert J, Ferrer A, Lao JI, Carrato C, López D, Ferrer I, Ariza A.

Neuroreport. 2006 Aug 21;17(12):1327-30.

PMID:
16951579
16.

Anti-aggregation and fibril-destabilizing effects of sex hormones on alpha-synuclein fibrils in vitro.

Hirohata M, Ono K, Morinaga A, Ikeda T, Yamada M.

Exp Neurol. 2009 Jun;217(2):434-9. doi: 10.1016/j.expneurol.2009.03.003. Epub 2009 Mar 13.

PMID:
19289119
17.
18.

Widespread and abundant alpha-synuclein pathology in a neurologically unimpaired subject.

Parkkinen L, Pirttilä T, Tervahauta M, Alafuzoff I.

Neuropathology. 2005 Dec;25(4):304-14.

PMID:
16382779
19.

Formation of dopamine-mediated alpha-synuclein-soluble oligomers requires methionine oxidation.

Leong SL, Pham CL, Galatis D, Fodero-Tavoletti MT, Perez K, Hill AF, Masters CL, Ali FE, Barnham KJ, Cappai R.

Free Radic Biol Med. 2009 May 15;46(10):1328-37. doi: 10.1016/j.freeradbiomed.2009.02.009. Epub 2009 Feb 25.

PMID:
19248830

Supplemental Content

Support Center